Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SLRN

Acelyrin Inc

Dec 01 • 04:00PM ET

6.88

Dollar change +0.16
Percentage change 2.38	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	37.02%	Shs Outstand	92.70M	Perf Week	-21.28%
Market Cap	669.01M	Forward P/E	-	EPS next Y	-4.38	Insider Trans	0.00%	Shs Float	61.24M	Perf Month	-24.64%
Income	-	PEG	-	EPS next Q	-1.00	Inst Own	68.89%	Short Float / Ratio	10.21% / 4.38	Perf Quarter	-74.63%
Sales	-	P/S	-	EPS this Y	64.89%	Inst Trans	-	Short Interest	6.25M	Perf Half Y	-60.69%
Book/sh	7.53	P/B	0.91	EPS next Y	40.90%	ROA	-	Target Price	30.75	Perf Year	-
Cash/sh	8.11	P/C	0.85	EPS next 5Y	-	ROE	-	52W Range	5.77 - 29.88	Perf YTD	-70.72%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-76.97%	Beta	-
Dividend %	-	Quick Ratio	11.88	Sales past 5Y	0.00%	Gross Margin	-	52W Low	19.24%	ATR	0.73
Employees	51	Current Ratio	11.88	Sales Q/Q	-	Oper. Margin	-	RSI (14)	34.57	Volatility	14.11% 8.15%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-452.98%	Profit Margin	-	Rel Volume	0.70	Prev Close	6.72
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 07 AMC	Payout	-	Avg Volume	1.43M	Price	6.88
Recom	1.40	SMA20	-18.08%	SMA50	-25.83%	SMA200	-60.58%	Volume	993,274	Change	2.38%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Sep-05-23	Initiated	H.C. Wainwright	Buy	$44
May-30-23	Initiated	TD Cowen	Outperform
May-30-23	Initiated	Piper Sandler	Overweight	$68
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Jefferies	Buy	$31

Nov-30-23 04:30PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire) +5.66%
Nov-28-23 05:55PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline (GlobeNewswire) -32.41%
01:44PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
Nov-27-23 09:09PM	Acelyrin blames CRO error for shocking phase 3 failure that sent shiver through biotech IPO market (FierceBiotech.com)
04:30PM	Loading…
04:30PM	ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program (GlobeNewswire)
Nov-20-23 11:01AM	Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Nov-16-23 06:42PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
04:11PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-07-23 05:11PM	Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing (GuruFocus.com)
04:05PM	ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-23 07:00AM	ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer (GlobeNewswire)
Oct-31-23 04:30PM	ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 (GlobeNewswire)
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-03-23 07:00AM	ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development (GlobeNewswire)
05:39PM	Loading…
Sep-15-23 05:39PM	Why Acelyrin Stock Plummeted 59% This Week (Motley Fool)
Sep-11-23 04:05PM	ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire)
Sep-06-23 07:00AM	ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-23 07:22PM	Billionaire Ken Griffin Pours Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks) +7.70%
Aug-14-23 04:05PM	ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-07-23 04:30PM	ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 (GlobeNewswire)
Jul-18-23 07:00AM	ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer (GlobeNewswire)
Jun-15-23 04:05PM	ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-09-23 04:10PM	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
May-05-23 07:08PM	Drug Developer Acelyrin Raises $540 Million in IPO (The Wall Street Journal)

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Westlake BioPartners Fund II,	10% Owner	May 09	Buy	18.00	1,250,000	22,500,000	9,790,729	May 11 09:16 PM
SEIDENBERG BETH C	Director	May 09	Buy	18.00	1,250,000	22,500,000	9,790,729	May 11 09:13 PM
SEIDENBERG BETH C	Director	May 09	Buy	18.00	60,000	1,080,000	60,000	May 11 09:13 PM
Gosebruch Henry O	Director	May 09	Buy	18.00	50,000	900,000	50,000	May 11 09:06 PM
Svoronos Dawn	Director	May 09	Buy	18.00	15,000	270,000	15,000	May 11 09:11 PM
Peloso Paul	Chief Medical Officer	May 09	Buy	18.00	6,000	108,000	6,000	May 11 08:54 PM
Dier Mardi	CFO and CBO	May 09	Buy	18.00	5,556	100,008	5,556	May 11 08:51 PM
Kim Mina	Chief Legal & Admin. Officer	May 09	Buy	18.00	5,000	90,000	5,000	May 11 08:58 PM
Becker Daniel J.	Director	May 09	Buy	18.00	3,000	54,000	3,000	May 11 09:02 PM
Dier Mardi	CFO and CBO	May 09	Buy	18.00	1,750	31,500	875	May 11 08:51 PM
Oyston Ronald	Chief People Officer	May 09	Buy	18.00	1,000	18,000	1,000	May 11 09:00 PM
Oyston Ronald	Chief People Officer	May 09	Buy	18.00	26	468	26	May 11 09:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLRN

Acelyrin Inc

Upgrade your FINVIZ experience